- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04271046
STAR Caregivers - Virtual Training and Follow-up (STAR-C-VTF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alzheimer's Disease and related dementias (ADRD) are debilitating conditions affecting more than 5 million Americans in 2014. With aging of the population it is projected that 8.4 million people will be diagnosed with ADRD over the next 15 years and health care costs attributable to ADRD are projected to be more than 1.2 trillion by 2050. Behavioral and Psychological Symptoms of Dementia (BPSD) (anxiety, agitation, depression) are common and often involve aggressive behavior towards family caregivers (CG) in response to unmet needs, discomfort, or frustration. BPSD are disturbing and frequently lead to caregivers seeking medication to control patient symptoms. Antipsychotic use in persons with dementia (PWD) more than doubles mortality risk; however, many caregivers are willing to accept those risks. The Choosing Wisely Guidelines from the American Psychiatric Association and American Geriatrics Society both recommend against prescribing antipsychotics as a first-line treatment for BPSD. STAR-Caregivers is an efficacious first-line behavioral treatment, endorsed by the Administration on Aging, that involves caregiver training to manage BPSD. However, the program has not been implemented widely - partly due to the cost of the programs, difficulty conducting outreach, and modality of training (in person with written materials). Adequate caregiver training and commensurate reduction in caregiver burden are the mediators (mechanisms) the Investigators will engage in this Stage III trial to reduce BPSD and discontinue antipsychotic medication use by PWD.
The STAR-Caregivers program is an education, training, and support intervention demonstrated efficacious in reducing BPSD. The original program involved 8 face-to-face, in-home training sessions and 4 follow-up phone calls. The condensed version involves 4 in-home sessions with 2 phone follow-ups.18 Neither of these is feasible from a payer perspective. The investigators propose to test a self-directed, remote version called STAR-virtual training and follow-up (STAR-VTF) that leverages secure email within the member portal at Kaiser Permanente Washington to improve access to training, fidelity to the STAR principles, and to lower the cost of the program.
The investigators propose a Stage III trial to ascertain the feasibility and acceptability of STAR-VTF in which (a) caregiver training materials are delivered electronically and learning is self-directed, (b) caregivers have one orientation phone visit with a social worker and (c) where caregivers receive ongoing support from a social worker via telephone and secure messaging in the web-based member portal. Investigators will compare outcomes in the STAR-VTF group to an attention control group (mailed material, links to websites, and generic secure messages).
The specific aims are:
Aim 1: Assess the feasibility and acceptability of conducting caregiver outreach, training, and support via social workers including: (1) willingness of caregivers to interact primarily through secure messaging (contact rates); and (2) willingness of caregivers to complete self-directed training (training completion rates).
Aim 2: Assess the feasibility and acceptability of the program from the payer perspective including: (1) average time spent per home-visit (including preparation and travel time); (2) average time per month spent responding to caregiver emails and coordinating care with primary care physicians; and (3 differences in face-to-face primary care, urgent care, and emergency department visit rates by PWD.
Aim 3: Test the hypotheses that (H1) caregiver participants in STAR-VTF will have lower levels of caregiver burden at 8 weeks and 6 months compared to an attention control group; and (H2) PWD participants in STAR-VTF will have lower rates of antipsychotic medication use at 6 months compared to control. Secondary outcomes are: caregiver depression and caregiver self-efficacy. The investigators propose to recruit 100 CG-PWD dyads (50 per arm).
This will be the first study to test a low intensity, self-directed caregiver training program with remote support from social workers. It will also be the first study to measure changes in antipsychotic medication use by PWD after caregiver training. Kaiser Permanente is an ideal setting because investigators have access to the complete electronic health record (EHR), prescription medication use, health care use, and demographic data. The investigators will be able to identify and enroll participants in real-time using an automated data "troll" as investigators have done previously. This study will be an important step in expanding access to training and support in a format that could be implemented within integrated delivery systems with capitated payments (i.e., Accountable Care Organizations). Growing use of EHR portals in these organizations will further increase demand for web-based care management/support. Demand will also increase as today's near-retirees, familiar with web-based applications, develop ADRD. Kaiser Permanente has pioneered such efforts and is the lead site in the Mental Health Research Network (MHRN). Findings from this study will inform a future multi-site pragmatic trial across the 13 health systems and 12 million enrollees in the MHRN.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98101
- Kaiser Permanente Washington Health Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Current Criteria:
Investigators will identify and recruit Person with Dementia-Caregiver dyads in which the person with dementia has has made a healthcare visit in the last week where a diagnosis of Alzheimer's Disease or related dementia was recorded. Because we will enroll dyads, there are inclusion/exclusion criteria for both.
Participants
Persons with dementia inclusion criteria:
Aged ≥ 65 years Confirmed diagnosis of Alzheimer's Disease related disorders (ADRD) from the patient Electronic Health Record (EHR) or primary care physician KP members for a minimum of 180 days prior to the index visit date. Expected to live >= 6 months from enrollment
Persons with dementia exclusion criteria:
- A diagnosis of bipolar disorder or schizophreniform disorder
- The primary care physician's opinion is that the person with dementia is expected to live less than 6 months.
- Less that 65 years of age
Caregiver inclusion criteria:
- Aged ≥ 21 years
- Lives with person with dementia or within 8 miles
- Provides at least 8 hours of care per week
- Able to read and speak English
- Have access to a computer or other device where they can access MyChart, personal email, and websites to complete online training
- Use MyChart to email the doctors that care for the PWD they are caring for
Caregivers exclusion criteria:
- Diagnosis of Alzheimer's Disease or related disorders.
- Less than 21 years of age
- Are not the spouse, or adult child with no siblings
- Unable to read and speak in English
- Do not have access to a computer or other device where they can access MyChart, personal email, and websites to complete online training
- Do not use MyChart to email to doctors that care for the PWD they are caring for.
Previous Criteria:
Participants
The investigators will identify and recruit Person with Dementia-Caregiver dyads in which the person with dementia has filled a new prescription for an antipsychotic medication. Because we will enroll dyads, there are inclusion/exclusion criteria for both.
Persons with dementia inclusion criteria:
- Aged ≥ 65 years
- Diagnosis of Alzheimer's Disease related dementia (ADRD)
- A new prescription for an antipsychotic medication
- Living at home
- Expected to live >= 6 months from enrollment
Persons with dementia exclusion criteria:
- A diagnosis of bipolar disorder or schizophreniform disorder
- Living in an assisted living, skilled nursing facility, or memory facility
- The primary care physician's opinion is that the person with dementia is expected to live less than 6 months.
Caregiver inclusion criteria:
- Aged ≥ 21 years
- Lives with person with dementia or within 8 miles
- Provides at least 8 hours of care per week
Caregivers exclusion criteria:
* Diagnosis of Alzheimer's Disease or related disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group- STAR-C-VTF
This study will use a parallel, two-arm randomized trial design. Participants will be 100 Person-with-Dementia-Caregiver dyads in which the person with dementia lives at home and recently filled a new prescription for antipsychotic medication. The experimental intervention will combine three elements:
Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period. |
|
Active Comparator: Control
One orientation phone visit with a coach. Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages. Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period. |
One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study.
Controls will receive usual care from their primary care provider and/or psychiatrist.
We will give participants an information package from the Alzheimer's Association including a list of resources.
To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia.
Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association.
This "attention control" is proposed to assess the additional impact of STAR-VTF above treatment as usual.
Investigators do not intend to track non-study training receipt in the control arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Caregiver Burden
Time Frame: Change from baseline caregiver burden at 8 weeks.
|
Self-reported caregiver burden assessed by the Disruption subscale on the Revised Memory and Behavior Problem Checklist (RMBPC) questionnaire.
The range in subscale scores is 0 to 32 with higher scores representing a worse outcome.
|
Change from baseline caregiver burden at 8 weeks.
|
Use of antipsychotic medications
Time Frame: 6 months after initial prescription
|
Refill rates after initial medication dispensing, using automated system pharmacy data
|
6 months after initial prescription
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Caregiver depression
Time Frame: Baseline, 8 week and 6 month follow up
|
Self-reported caregiver depression assessed by the 8-item Patient Health Questionnaire (PHQ-8). The PHQ-8 is am eight-item measure of depression that assesses symptoms over the last two weeks. The total sum of the 8 responses from the PHQ-8 ranges between 0 and 24 with higher scores indicating worse outcome. In general, a total of 10 or above is suggestive of the presence of depression. |
Baseline, 8 week and 6 month follow up
|
Change in Caregiver self-efficacy
Time Frame: Change from baseline caregiver mastery at 8 weeks.
|
Self-reported caregiver self-efficacy assessed by the Caregiver Mastery Scale. Total scores can range from 7 to 35, with higher scores reflecting greater caregiver mastery. The Caregiver Mastery Scale is a 7-item measure of self-efficacy. is a 7-item self-report scale, indicating the extent to which respondents agree (5) or disagree (1) with each item. Three items with negative statements are reverse-scored. Total scores can range from 7 to 35, with higher scores reflecting greater caregiver mastery. |
Change from baseline caregiver mastery at 8 weeks.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study Participation Rate
Time Frame: 8 weeks from baseline
|
We will report study participation rates by study arm at the end of training
|
8 weeks from baseline
|
Response Rates for Surveys
Time Frame: 8 weeks from baseline
|
We will report survey response rates by study arm at the end of the trial.
|
8 weeks from baseline
|
Number of Dyads Who Complete Training
Time Frame: 8 weeks from baseline
|
We will report completion rates by study arm at the end of the trial.
Completion will be defined as completing 2 home-based visits, 1 phone-based visit and sending at least one secure message to a social worker in the baseline to 8-week period and one message in weeks 9 through 24.
|
8 weeks from baseline
|
Number of Primary Care Visits
Time Frame: End of follow-up (6 months)
|
Measured as the number of visits per eligible study participant during the study period.
|
End of follow-up (6 months)
|
Number of Urgent Care Visits
Time Frame: End of follow-up (6 months)
|
Measured as the number of visits per eligible study participant during the study period.
|
End of follow-up (6 months)
|
Number of Emergency Department Visits
Time Frame: End of follow-up (6 months)
|
Measured as the number of visits per eligible study participant during the study period.
|
End of follow-up (6 months)
|
Number of secure messages
Time Frame: End of follow-up (6 months)
|
Count of the number of caregiver-initiated secure messages to the coach
|
End of follow-up (6 months)
|
Time per home visit
Time Frame: baseline only
|
Total time spent traveling to/from and conducting the home-based visit at baseline
|
baseline only
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1347434
- 1R01AG061926-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on STAR-C-VTF
-
University of WashingtonAlzheimer's AssociationRecruitingDementia | Alzheimer DiseaseUnited States
-
University of WashingtonNational Institute on Aging (NIA); Kaiser PermanenteCompletedBehavioral Symptoms | Dementia | Alzheimer Disease | Caregiver BurdenUnited States
-
Umeå UniversityRegion VästerbottenNot yet recruiting
-
University of California, San FranciscoSan Francisco Department of Public Health; San Francisco General Hospital; Sonoma...CompletedType 2 Diabetes Mellitus | Gestational Diabetes MellitusUnited States
-
Stryker Trauma GmbHCompleted
-
University Hospital Inselspital, BerneCompletedChronic Pelvic Pain SyndromeSwitzerland
-
Encore Medical, L.P.CompletedOsteoarthritis | Rheumatoid Arthritis | Post Traumatic Arthritis | Primary ArthrosisUnited States
-
Miulli General HospitalActive, not recruiting
-
University of New MexicoCompletedSimulator-based Training of Ultrasound-guided Regional AnesthesiaUnited States
-
University Hospital Inselspital, BerneCompletedChronic Pelvic Pain SyndromeSwitzerland